Cargando…
Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial
AIM: The primary objective was to compare apixaban to heparin/vitamin K antagonist (VKA) in patients with atrial fibrillation (AF) and ≤48 h anticoagulation prior to randomization undergoing cardioversion. METHODS: One thousand five hundred patients were randomized. The apixaban dose of 5 mg b.i.d....
Autores principales: | Ezekowitz, Michael D, Pollack, Charles V, Halperin, Jonathan L, England, Richard D, VanPelt Nguyen, Sandra, Spahr, Judith, Sudworth, Maria, Cater, Nilo B, Breazna, Andrei, Oldgren, Jonas, Kirchhof, Paulus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6110194/ https://www.ncbi.nlm.nih.gov/pubmed/29659797 http://dx.doi.org/10.1093/eurheartj/ehy148 |
Ejemplares similares
-
Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation
por: Kirchhof, Paulus, et al.
Publicado: (2018) -
Patiromer for the management of hyperkalemia in heart failure with reduced
ejection fraction: the DIAMOND trial( )
por: Butler, Javed, et al.
Publicado: (2022) -
Attaining sinus rhythm mediates improved outcome with early rhythm control therapy of atrial fibrillation: the EAST-AFNET 4 trial( )
por: Eckardt, Lars, et al.
Publicado: (2022) -
Anisotropic Isolation by Distance: The Main Orientations of Human Genetic Differentiation
por: Jay, Flora, et al.
Publicado: (2013) -
Good Codons, Bad Transcript: Large Reductions in Gene Expression and Fitness Arising from Synonymous Mutations in a Key Enzyme
por: Agashe, Deepa, et al.
Publicado: (2013)